Single User License
INR 135120
Site License
INR 270240
Corporate User License
INR 405360

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Head And Neck Cancer-Pipeline Review, H1 2015

Head And Neck Cancer-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Head And Neck Cancer-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Head And Neck Cancer-Pipeline Review, H1 2015', provides an overview of the Head And Neck Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Head And Neck Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Head And Neck Cancer

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Head And Neck Cancer and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Head And Neck Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Head And Neck Cancer pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Head And Neck Cancer

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Head And Neck Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

Introduction 8

Head And Neck Cancer Overview 9

Therapeutics Development 10

Head And Neck Cancer-Therapeutics under Development by Companies 12

Head And Neck Cancer-Therapeutics under Investigation by Universities/Institutes 22

Head And Neck Cancer-Pipeline Products Glance 25

Head And Neck Cancer-Products under Development by Companies 29

Head And Neck Cancer-Products under Investigation by Universities/Institutes 41

Head And Neck Cancer-Companies Involved in Therapeutics Development 44

Head And Neck Cancer-Therapeutics Assessment 156

Drug Profiles 180

Head And Neck Cancer-Recent Pipeline Updates 513

Head And Neck Cancer-Dormant Projects 673

Head And Neck Cancer-Discontinued Products 683

Head And Neck Cancer-Product Development Milestones 684

Appendix 692

List of Tables

Number of Products under Development for Head And Neck Cancer, H1 2015 31

Number of Products under Development for Head And Neck Cancer-Comparative Analysis, H1 2015 32

Number of Products under Development by Companies, H1 2015 34

Number of Products under Development by Companies, H1 2015 (Contd..1) 35

Number of Products under Development by Companies, H1 2015 (Contd..2) 36

Number of Products under Development by Companies, H1 2015 (Contd..3) 37

Number of Products under Development by Companies, H1 2015 (Contd..4) 38

Number of Products under Development by Companies, H1 2015 (Contd..5) 39

Number of Products under Development by Companies, H1 2015 (Contd..6) 40

Number of Products under Development by Companies, H1 2015 (Contd..7) 41

Number of Products under Development by Companies, H1 2015 (Contd..8) 42

Number of Products under Investigation by Universities/Institutes, H1 2015 44

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 45

Comparative Analysis by Late Stage Development, H1 2015 46

Comparative Analysis by Clinical Stage Development, H1 2015 47

Comparative Analysis by Early Stage Development, H1 2015 48

Comparative Analysis by Unknown Stage Development, H1 2015 49

Products under Development by Companies, H1 2015 50

Products under Development by Companies, H1 2015 (Contd..1) 51

Products under Development by Companies, H1 2015 (Contd..2) 52

Products under Development by Companies, H1 2015 (Contd..3) 53

Products under Development by Companies, H1 2015 (Contd..4) 54

Products under Development by Companies, H1 2015 (Contd..5) 55

Products under Development by Companies, H1 2015 (Contd..6) 56

Products under Development by Companies, H1 2015 (Contd..7) 57

Products under Development by Companies, H1 2015 (Contd..8) 58

Products under Development by Companies, H1 2015 (Contd..9) 59

Products under Development by Companies, H1 2015 (Contd..10) 60

Products under Development by Companies, H1 2015 (Contd..11) 61

Products under Investigation by Universities/Institutes, H1 2015 62

Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 63

Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 64

Head And Neck Cancer-Pipeline by 3M Drug Delivery Systems, H1 2015 65

Head And Neck Cancer-Pipeline by AB Science, H1 2015 66

Head And Neck Cancer-Pipeline by Acceleron Pharma, Inc., H1 2015 67

Head And Neck Cancer-Pipeline by Advaxis, Inc., H1 2015 68

Head And Neck Cancer-Pipeline by Ambrx, Inc., H1 2015 69

Head And Neck Cancer-Pipeline by Amgen Inc., H1 2015 70

Head And Neck Cancer-Pipeline by arGEN-X BV, H1 2015 71

Head And Neck Cancer-Pipeline by ArQule, Inc., H1 2015 72

Head And Neck Cancer-Pipeline by Ascenta Therapeutics, Inc., H1 2015 73

Head And Neck Cancer-Pipeline by Astellas Pharma Inc., H1 2015 74

Head And Neck Cancer-Pipeline by AstraZeneca PLC, H1 2015 75

Head And Neck Cancer-Pipeline by AVEO Pharmaceuticals, Inc., H1 2015 76

Head And Neck Cancer-Pipeline by Bayer AG, H1 2015 77

Head And Neck Cancer-Pipeline by Bexion Pharmaceuticals, LLC., H1 2015 78

Head And Neck Cancer-Pipeline by Bio-Path Holdings, Inc., H1 2015 79

Head And Neck Cancer-Pipeline by BioDiem Ltd, H1 2015 80

Head And Neck Cancer-Pipeline by Bionomics Limited, H1 2015 81

Head And Neck Cancer-Pipeline by Biotest AG, H1 2015 82

Head And Neck Cancer-Pipeline by Boehringer Ingelheim GmbH, H1 2015 83

Head And Neck Cancer-Pipeline by Boston Biomedical, Inc., H1 2015 84

Head And Neck Cancer-Pipeline by Bristol-Myers Squibb Company, H1 2015 85

Head And Neck Cancer-Pipeline by CEL-SCI Corporation, H1 2015 86

Head And Neck Cancer-Pipeline by Celgene Corporation, H1 2015 87

Head And Neck Cancer-Pipeline by Cellceutix Corporation, H1 2015 88

Head And Neck Cancer-Pipeline by Celldex Therapeutics, Inc., H1 2015 89

Head And Neck Cancer-Pipeline by Celltrion, Inc., H1 2015 90

Head And Neck Cancer-Pipeline by Centrose Llc, H1 2015 91

Head And Neck Cancer-Pipeline by CTI BioPharma Corp., H1 2015 92

Head And Neck Cancer-Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2015 93

Head And Neck Cancer-Pipeline by CytomX Therapeutics, Inc., H1 2015 94

Head And Neck Cancer-Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2015 95

Head And Neck Cancer-Pipeline by Daiichi Sankyo Company, Limited, H1 2015 96

Head And Neck Cancer-Pipeline by EcoBiotics Limited, H1 2015 97

Head And Neck Cancer-Pipeline by Eisai Co., Ltd., H1 2015 98

Head And Neck Cancer-Pipeline by Eli Lilly and Company, H1 2015 99

Head And Neck Cancer-Pipeline by EntreChem, S.L., H1 2015 100

Head And Neck Cancer-Pipeline by Etubics Corporation, H1 2015 101

Head And Neck Cancer-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 102

Head And Neck Cancer-Pipeline by Genelux Corporation, H1 2015 103

Head And Neck Cancer-Pipeline by Genentech, Inc., H1 2015 104

Head And Neck Cancer-Pipeline by Genexine, Inc., H1 2015 105

Head And Neck Cancer-Pipeline by Genmab A/S, H1 2015 106

Head And Neck Cancer-Pipeline by GlaxoSmithKline plc, H1 2015 107

Head And Neck Cancer-Pipeline by Gliknik, Inc., H1 2015 108

Head And Neck Cancer-Pipeline by Glycotope GmbH, H1 2015 109

Head And Neck Cancer-Pipeline by Green Cross Corporation, H1 2015 110

Head And Neck Cancer-Pipeline by ImmunoGen, Inc., H1 2015 111

Head And Neck Cancer-Pipeline by Immunomedics, Inc., H1 2015 112

Head And Neck Cancer-Pipeline by Immunovative Therapies, Ltd., H1 2015 113

Head And Neck Cancer-Pipeline by Incuron, LLC, H1 2015 114

Head And Neck Cancer-Pipeline by Incyte Corporation, H1 2015 115

Head And Neck Cancer-Pipeline by Innate Pharma SA, H1 2015 116

Head And Neck Cancer-Pipeline by Inovio Pharmaceuticals, Inc., H1 2015 117

Head And Neck Cancer-Pipeline by InteRNA Technologies B.V., H1 2015 118

Head And Neck Cancer-Pipeline by ISU ABXIS Co.,Ltd., H1 2015 119

Head And Neck Cancer-Pipeline by Jiangsu Kanion Pharmaceutical Co., Ltd., H1 2015 120

Head And Neck Cancer-Pipeline by Karyopharm Therapeutics, Inc., H1 2015 121

Head And Neck Cancer-Pipeline by Laboratoires Pierre Fabre SA, H1 2015 122

Head And Neck Cancer-Pipeline by Lytix Biopharma AS, H1 2015 123

Head And Neck Cancer-Pipeline by Mabion SA, H1 2015 124

Head And Neck Cancer-Pipeline by MacroGenics, Inc., H1 2015 125

Head And Neck Cancer-Pipeline by Marsala Biotech Inc., H1 2015 126

Head And Neck Cancer-Pipeline by MedImmune, LLC, H1 2015 127

Head And Neck Cancer-Pipeline by Merck & Co., Inc., H1 2015 128

Head And Neck Cancer-Pipeline by Merck KGaA, H1 2015 129

Head And Neck Cancer-Pipeline by Merrimack Pharmaceuticals, Inc., H1 2015 130

Head And Neck Cancer-Pipeline by Mirati Therapeutics Inc., H1 2015 131

Head And Neck Cancer-Pipeline by Mission Therapeutics Ltd, H1 2015 132

Head And Neck Cancer-Pipeline by Molplex Ltd., H1 2015 133

Head And Neck Cancer-Pipeline by Multimmune GmbH, H1 2015 134

Head And Neck Cancer-Pipeline by Nanobiotix, H1 2015 135

Head And Neck Cancer-Pipeline by Natco Pharma Limited, H1 2015 136

Head And Neck Cancer-Pipeline by Novartis AG, H1 2015 137

Head And Neck Cancer-Pipeline by Omnitura Therapeutics Inc., H1 2015 138

Head And Neck Cancer-Pipeline by Oncobiologics, Inc., H1 2015 139

Head And Neck Cancer-Pipeline by Oncolys BioPharma Inc., H1 2015 140

Head And Neck Cancer-Pipeline by Oncolytics Biotech Inc., H1 2015 141

Head And Neck Cancer-Pipeline by Onconova Therapeutics, Inc., H1 2015 142

Head And Neck Cancer-Pipeline by OncoSec Medical Inc., H1 2015 143

Head And Neck Cancer-Pipeline by Oncovir, Inc., H1 2015 144

Head And Neck Cancer-Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 145

Head And Neck Cancer-Pipeline by Otsuka Holdings Co., Ltd., H1 2015 146

Head And Neck Cancer-Pipeline by OXiGENE, Inc., H1 2015 147

Head And Neck Cancer-Pipeline by Panacea Biotec Limited, H1 2015 148

Head And Neck Cancer-Pipeline by PCI Biotech AS, H1 2015 149

Head And Neck Cancer-Pipeline by Pfizer Inc., H1 2015 150

Head And Neck Cancer-Pipeline by Pharmacyclics, Inc., H1 2015 151

Head And Neck Cancer-Pipeline by Pique Therapeutics, H1 2015 152

Head And Neck Cancer-Pipeline by Piramal Enterprises Limited, H1 2015 153

Head And Neck Cancer-Pipeline by PlantForm Corporation, H1 2015 154

Head And Neck Cancer-Pipeline by PNP Therapeutics, Inc., H1 2015 155

Head And Neck Cancer-Pipeline by Profectus BioSciences, Inc., H1 2015 156

Head And Neck Cancer-Pipeline by Sareum Holdings plc, H1 2015 157

Head And Neck Cancer-Pipeline by Selecta Biosciences, Inc., H1 2015 158

Head And Neck Cancer-Pipeline by SentoClone International AB, H1 2015 159

Head And Neck Cancer-Pipeline by Serina Therapeutics, Inc., H1 2015 160

Head And Neck Cancer-Pipeline by Shionogi & Co., Ltd., H1 2015 161

Head And Neck Cancer-Pipeline by Silence Therapeutics plc, H1 2015 162

Head And Neck Cancer-Pipeline by SillaJen Co. Ltd., H1 2015 163

Head And Neck Cancer-Pipeline by Synta Pharmaceuticals Corp., H1 2015 164

Head And Neck Cancer-Pipeline by Takara Bio Inc., H1 2015 165

Head And Neck Cancer-Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 166

Head And Neck Cancer-Pipeline by Theravectys S.A., H1 2015 167

Head And Neck Cancer-Pipeline by Transgene SA, H1 2015 168

Head And Neck Cancer-Pipeline by VasGene Therapeutics, Inc., H1 2015 169

Head And Neck Cancer-Pipeline by VentiRx Pharmaceuticals, Inc., H1 2015 170

Head And Neck Cancer-Pipeline by Virttu Biologics Limited, H1 2015 171

Head And Neck Cancer-Pipeline by Viventia Biotechnologies Inc., H1 2015 172

Head And Neck Cancer-Pipeline by VLPbio, H1 2015 173

Head And Neck Cancer-Pipeline by VM Discovery, Inc., H1 2015 174

Head And Neck Cancer-Pipeline by Zhejiang BetaPharma Co., Ltd., H1 2015 175

Head And Neck Cancer-Pipeline by Zyngenia, Inc., H1 2015 176

Assessment by Monotherapy Products, H1 2015 177

Assessment by Combination Products, H1 2015 178

Number of Products by Stage and Target, H1 2015 180

Number of Products by Stage and Mechanism of Action, H1 2015 190

Number of Products by Stage and Route of Administration, H1 2015 198

Number of Products by Stage and Molecule Type, H1 2015 200

Head And Neck Cancer Therapeutics-Recent Pipeline Updates, H1 2015 534

Head And Neck Cancer-Dormant Projects, H1 2015 694

Head And Neck Cancer-Dormant Projects (Contd..1), H1 2015 695

Head And Neck Cancer-Dormant Projects (Contd..2), H1 2015 696

Head And Neck Cancer-Dormant Projects (Contd..3), H1 2015 697

Head And Neck Cancer-Dormant Projects (Contd..4), H1 2015 698

Head And Neck Cancer-Dormant Projects (Contd..5), H1 2015 699

Head And Neck Cancer-Dormant Projects (Contd..6), H1 2015 700

Head And Neck Cancer-Dormant Projects (Contd..7), H1 2015 701

Head And Neck Cancer-Dormant Projects (Contd..8), H1 2015 702

Head And Neck Cancer-Dormant Projects (Contd..9), H1 2015 703

Head And Neck Cancer-Discontinued Products, H1 2015 704

List of Figures

Number of Products under Development for Head And Neck Cancer, H1 2015 31

Number of Products under Development for Head And Neck Cancer-Comparative Analysis, H1 2015 32

Number of Products under Development by Companies, H1 2015 33

Number of Products under Investigation by Universities/Institutes, H1 2015 43

Comparative Analysis by Late Stage Development, H1 2015 46

Comparative Analysis by Clinical Stage Development, H1 2015 47

Comparative Analysis by Early Stage Products, H1 2015 48

Assessment by Monotherapy Products, H1 2015 177

Assessment by Combination Products, H1 2015 178

Number of Products by Top 10 Targets, H1 2015 179

Number of Products by Stage and Top 10 Targets, H1 2015 179

Number of Products by Top 10 Mechanism of Actions, H1 2015 189

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 189

Number of Products by Top 10 Routes of Administration, H1 2015 197

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 197

Number of Products by Top 10 Molecule Types, H1 2015 199

Number of Products by Stage and Top 10 Molecule Types, H1 2015 199

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

3M Drug Delivery Systems

AB Science

Acceleron Pharma, Inc.

Advaxis, Inc.

Ambrx, Inc.

Amgen Inc.

arGEN-X BV

ArQule, Inc.

Ascenta Therapeutics, Inc.

Astellas Pharma Inc.

AstraZeneca PLC

AVEO Pharmaceuticals, Inc.

Bayer AG

Bexion Pharmaceuticals, LLC.

Bio-Path Holdings, Inc.

BioDiem Ltd

Bionomics Limited

Biotest AG

Boehringer Ingelheim GmbH

Boston Biomedical, Inc.

Bristol-Myers Squibb Company

CEL-SCI Corporation

Celgene Corporation

Cellceutix Corporation

Celldex Therapeutics, Inc.

Celltrion, Inc.

Centrose Llc

CTI BioPharma Corp.

Cyclacel Pharmaceuticals, Inc.

CytomX Therapeutics, Inc.

Daewoong Pharmaceutical Co., Ltd.

Daiichi Sankyo Company, Limited

EcoBiotics Limited

Eisai Co., Ltd.

Eli Lilly and Company

EntreChem, S.L.

Etubics Corporation

F. Hoffmann-La Roche Ltd.

Genelux Corporation

Genentech, Inc.

Genexine, Inc.

Genmab A/S

GlaxoSmithKline plc

Gliknik, Inc.

Glycotope GmbH

Green Cross Corporation

ImmunoGen, Inc.

Immunomedics, Inc.

Immunovative Therapies, Ltd.

Incuron, LLC

Incyte Corporation

Innate Pharma SA

Inovio Pharmaceuticals, Inc.

InteRNA Technologies B.V.

ISU ABXIS Co.,Ltd.

Jiangsu Kanion Pharmaceutical Co., Ltd.

Karyopharm Therapeutics, Inc.

Laboratoires Pierre Fabre SA

Lytix Biopharma AS

Mabion SA

MacroGenics, Inc.

Marsala Biotech Inc.

MedImmune, LLC

Merck & Co., Inc.

Merck KGaA

Merrimack Pharmaceuticals, Inc.

Mirati Therapeutics Inc.

Mission Therapeutics Ltd

Molplex Ltd.

Multimmune GmbH

Nanobiotix

Natco Pharma Limited

Novartis AG

Omnitura Therapeutics Inc.

Oncobiologics, Inc.

Oncolys BioPharma Inc.

Oncolytics Biotech Inc.

Onconova Therapeutics, Inc.

OncoSec Medical Inc.

Oncovir, Inc.

Ono Pharmaceutical Co., Ltd.

Otsuka Holdings Co., Ltd.

OXiGENE, Inc.

Panacea Biotec Limited

PCI Biotech AS

Pfizer Inc.

Pharmacyclics, Inc.

Pique Therapeutics

Piramal Enterprises Limited

PlantForm Corporation

PNP Therapeutics, Inc.

Profectus BioSciences, Inc.

Sareum Holdings plc

Selecta Biosciences, Inc.

SentoClone International AB

Serina Therapeutics, Inc.

Shionogi & Co., Ltd.

Silence Therapeutics plc

SillaJen Co. Ltd.

Synta Pharmaceuticals Corp.

Takara Bio Inc.

Teva Pharmaceutical Industries Limited

Theravectys S.A.

Transgene SA

VasGene Therapeutics, Inc.

VentiRx Pharmaceuticals, Inc.

Virttu Biologics Limited

Viventia Biotechnologies Inc.

VLPbio

VM Discovery, Inc.

Zhejiang BetaPharma Co., Ltd.

Zyngenia, Inc.

Head And Neck Cancer Therapeutic Products under Development, Key Players in Head And Neck Cancer Therapeutics, Head And Neck Cancer Pipeline Overview, Head And Neck Cancer Pipeline, Head And Neck Cancer Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com